Perampanel is a selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy. Accoding to
Nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy. The trial evaluated patients
Gilead Sciences generated a net income of $629.42m for the fourth quarter 2010, or $0.76 per diluted share, compared to $802.21m, or $0.87 per diluted share, against the
In total, the company has already received Orphan drug designation for vaccines for pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia. BioSante Pharma president and CEO Stephen
ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of all forms of ATTR, which includes FAP and familial amyloidotic cardiomyopathy (FAC). Alnylam Regulatory Affairs
The new tools and systems are anticipated to allow NuVax to develop three separate cancer therapeutics for the treatment of Multi Myeloma, Pancreatic Cancer and Lung Cancer. As
Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this
The company has posted a net income of $5.63m for the fourth quarter 2010, or $0.14 per diluted share, compared to $5.81m, or $0.15 per diluted share, for
CBLB502 is said to a bioengineered derivative of a microbial protein that helps in reducing injury from acute stresses, such as radiation and chemotherapy. Cleveland BioLabs Public Health
Under a contract with the Henry M Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.